A supplementation with 15 mg/day of HT combined with chemotherapy treatment based on epirubicin plus cyclophosphamide decreases plasma levels of TIMP-1 in women with luminal subtype breast cancer, showing that the selected combination is of choice for improving the prognosis of patients with this pathology. The gene discussed is TIMP1; the disease is breast carcinoma.